Susquehanna Fundamental Investments LLC Purchases Shares of 343,414 Novavax, Inc. (NASDAQ:NVAX)

Susquehanna Fundamental Investments LLC acquired a new position in shares of Novavax, Inc. (NASDAQ:NVAX) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 343,414 shares of the biopharmaceutical company’s stock, valued at approximately $2,761,000. Susquehanna Fundamental Investments LLC owned approximately 0.21% of Novavax as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Franklin Resources Inc. lifted its holdings in shares of Novavax by 300.4% during the 3rd quarter. Franklin Resources Inc. now owns 97,162 shares of the biopharmaceutical company’s stock valued at $1,226,000 after purchasing an additional 72,894 shares during the last quarter. Shah Capital Management raised its stake in Novavax by 13.6% in the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock valued at $89,637,000 after buying an additional 1,333,305 shares during the last quarter. Arizona State Retirement System boosted its holdings in Novavax by 14.9% in the fourth quarter. Arizona State Retirement System now owns 41,793 shares of the biopharmaceutical company’s stock worth $336,000 after acquiring an additional 5,407 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Novavax by 0.4% during the fourth quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company’s stock worth $3,509,000 after acquiring an additional 1,664 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Novavax by 6.7% during the fourth quarter. Rhumbline Advisers now owns 208,464 shares of the biopharmaceutical company’s stock valued at $1,676,000 after acquiring an additional 13,024 shares in the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Stock Performance

NASDAQ:NVAX opened at $6.42 on Wednesday. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -2.84, a PEG ratio of 2.85 and a beta of 3.15. The firm’s fifty day moving average is $7.07 and its two-hundred day moving average is $8.27. Novavax, Inc. has a one year low of $4.25 and a one year high of $23.86.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to analysts’ expectations of $85.48 million. During the same period last year, the company posted ($1.44) earnings per share. As a group, equities research analysts predict that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on NVAX shares. TD Cowen raised shares of Novavax to a “hold” rating in a research report on Thursday, February 27th. BTIG Research assumed coverage on shares of Novavax in a report on Friday, February 28th. They set a “buy” rating and a $19.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $18.00.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.